Skip to content

Whole Exome Sequencing of Familial and Pediatric Forms of Vasculitis

Identification of Susceptibility Loci and Genes for Systemic Vasculitis Risk, by Analyzing Whole Exome Sequencing of Familial and Pediatric Forms of Vasculitis (FAMILYVASC Study)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04006535
Acronym
FAMILYVASC
Enrollment
100
Registered
2019-07-05
Start date
2019-06-01
Completion date
2029-06-01
Last updated
2019-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vasculitis

Keywords

Vasculitis

Brief summary

The FAMILYVASC study is a prospective observational study which will aim to identify susceptibility loci and genes for systemic vasculitis risk in patients with familial or pediatric forms of vasculitis. Genetic analysis based on whole exome sequencing will be carried out through salivary DNA.

Interventions

GENETICgenetic analysis

Saliva sample collection for genetic analysis

Sponsors

Benjamin Terrier
Lead SponsorOTHER

Study design

Observational model
FAMILY_BASED
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

for subjects with vasculitis * Children and adults * Patients with vasculitis, as defined in the Chapel Hill International Classification in its revised version of 2012 * Patient information and signed informed consent * Pregnant and breastfeeding women can be included in the study Inclusion criteria for healthy subjects * Children and adults * Do not have vasculitis, as defined in the Chapel Hill International Classification in its revised version of 2012, or relatives on the 1st; 2nd; 3rd or 4th degree of a patient with vasculitis * Patient information and signed informed consent * Pregnant and breastfeeding women can be included in the study

Exclusion criteria

* Refusal of consent or inability to obtain consent * Dementia or unauthorized patient, for psychiatric or intellectual failure reasons, to receive information about the protocol and to give informed consent. * Uncooperative patient, or any pathology that could make the patient potentially non-compliant to the study procedures, and patients interned for regulatory or legal reasons.

Design outcomes

Primary

MeasureTime frame
Identification of susceptibility loci and genesAt the moment of enrollment

Countries

France

Contacts

Primary ContactBenjamin Terrier, MD, PhD
benjamin.terrier@aphp.fr+33 1 58 41 14 61
Backup ContactHicham Kardaoui, MSc
hicham.kardaoui@aphp.fr+33 1 58 41 16 46

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026